takeda_usa_pharmaceuticals_u

Takeda’s Ninlaro clears Phase 3 endpoint as maintenance therapy in multiple myeloma

pharmafile | July 12, 2018 | News story | Medical Communications, Research and Development |  Ninlaro, Takeda, multiple myeloma, pharma 

After making headlines with its mammoth deal to acquire Shire earlier this year, Takeda has emerged with new Phase 3 data for its oral proteasome inhibitor Ninlaro (ixazomib).

The findings showed that the drug met its primary endpoint with a statistically significant improvement in progression-free survival (PFS) versus placebo as a maintenance therapy for multiple myeloma in adult patients who responded to high-dose therapy (HDT) and autologous stem cell transplant (ASCT).  

Additionally, no new safety signals were found during the trial, with Ninlaro’s safety and efficacy profile remaining consistent with the findings of previous studies.

Advertisement

“Within the maintenance setting, it is critical that we find agents that are efficacious, tolerable and convenient,” commented Dr Jesús Gomez Navarro, Vice President, Head of Oncology Clinical Research and Development at Takeda. “The results of the TOURMALINE-MM3 trial represent an important step toward the goal of expanding the use of Ninlaro as a maintenance therapy. This is the first and only Phase 3 placebo-controlled study evaluating a proteasome inhibitor in this setting and we look forward to discussions with Health Authorities around the world.”

Ninlaro is not currently approved anywhere in the aforementioned indication, but Takeda has confirmed it will present full details of the study at the 60th American Society of Hematology Annual Meeting in December in support of regulatory submissions in the near future.

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Von Willebrand disease – increasing awareness and access to vital care

Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …

The Gateway to Local Adoption Series

Latest content